[
    {
        "utterance": "Matt Bogyo: some intros just so we all know again about what people do. Uh just as a reminder what my background is uh chemistry and specifically um synthesis of mainly optical based probes. We do a little bit of pet and now some ultrasound as well. Um but mainly yeah trying to develop agents that can report on specific biological signatures namely proteolytic signatures is what we do a lot of. Um not we don't do that much metabolite stuff but we we are starting to get interested more in lipid metabolites as well. Um so I I think it's easiest if I just call out people looking around the top of my screen here so maybe start with Molly. I know you're eating sorry. ",
        "annotations": {
            "signal expertise": "Matt explicitly states his background and expertise in chemistry and his work on optical-based probes.",
            "express humor": "Matt makes a lighthearted comment about Molly eating.",
            "encourage participation": "Matt suggests calling out people to contribute, starting with Molly."
        }
    },
    {
        "utterance": "Jin Zhang: Sorry, sorry. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Matt Bogyo: Okay, let's go to Kevin. Let's let's go to Kevin. ",
        "annotations": {
            "process management": "Matt Bogyo is managing the meeting flow by deciding whose turn it is to speak next.",
            "encourage participation": "Matt Bogyo is inviting Kevin to contribute by saying 'let's go to Kevin'."
        }
    },
    {
        "utterance": "Jin Zhang: Matt, can I um intervene? Sorry, before everything, um can we uh identify a reporter um uh recorder/reporter from this group? If you have done the job uh previously, you you don't have to do it or uh and um anyone else can we have a volunteer? ",
        "annotations": {
            "ask question": "Jin Zhang is requesting information or action from the group, specifically about identifying a reporter/recorder.",
            "process management": "Jin Zhang is managing the process of organizing the group's activities or roles by asking about identifying a reporter/recorder."
        }
    },
    {
        "utterance": "Kevin Cash: Sure, I can do it. ",
        "annotations": {
            "assign task": "Kevin Cash is accepting the role of reporter/recorder, thereby taking on a task assigned to him through volunteering.",
            "supportive response": "Kevin's response is also a supportive one as it agrees with and supports the group's need for a reporter/recorder."
        }
    },
    {
        "utterance": "Jin Zhang: Great. Thanks, Kevin. And um do you want to uh set up a Google Doc? Would that is is that possible? And then we can sort of do the notes there and then copy and paste. ",
        "annotations": {
            "propose new idea": "Jin Zhang introduces the idea of using a Google Doc for note-taking.",
            "process management": "Jin Zhang suggests a method for managing meeting notes, which involves setting up a Google Doc."
        }
    },
    {
        "utterance": "Kevin Cash: Sure, I can do that. ",
        "annotations": {
            "Supportive response": "Kevin is expressing agreement and validation to Jin Zhang's request by agreeing to take on the role of reporter/recorder."
        }
    },
    {
        "utterance": "Jin Zhang: Okay, great. And um if you can share that link and other people can also um add uh additional comments notes to that doc. Uh sorry Matt for introduce the introduction. We probably want to have the reporter sort it out. ",
        "annotations": {
            "process management": "Jin Zhang is making arrangements for collaboration on a document and managing how the group contributes to it.",
            "assign task": "Jin Zhang is assigning or suggesting tasks to Kevin (sharing a link) and to the reporter (sorting out the document)."
        }
    },
    {
        "utterance": "Matt Bogyo: No, you can. ",
        "annotations": {
            "acknowledge contribution": "Matt Bogyo is verbally recognizing Jin Zhang's input.",
            "supportive response": "Matt Bogyo is expressing agreement or validation."
        }
    },
    {
        "utterance": "Jin Zhang: And also I wonder if we want to take one minute to write down some thoughts uh about this topic and then because quite often when the intro starts, um you know that naturally go into the the discussion. ",
        "annotations": {
            "process management": "Jin Zhang is suggesting a process for the group to follow, which is to take a minute to write down their thoughts before moving into discussion.",
            "encourage participation": "By asking group members to write down their thoughts, Jin Zhang is encouraging them to participate and contribute their ideas."
        }
    },
    {
        "utterance": "Matt Bogyo: Sure, yeah, you can do it that way. That's fine. ",
        "annotations": {
            "supportive response": "Matt Bogyo is expressing agreement and validation of Jin Zhang's suggestion without adding new content.",
            "process management": "Matt Bogyo is agreeing to a process suggested by Jin Zhang, which involves managing how the discussion proceeds."
        }
    },
    {
        "utterance": "Jin Zhang: Right, sorry. I promise after this I'll let you take over. Okay, maybe we take one minute to write down actually for you know uh past a few sessions we didn't have to go to these notes but just in case um we take you know maybe one minute to write down some thoughts about this topic. Again, um it's about metabolites uh I think there are some suggested topics um can uh metabolic imaging be used diagnostically uh mass spec imaging is leading the way um but can that be used together with other imaging methodologies. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by indicating a transition and ensuring the discussion stays on track.",
            "encourage participation": "The speaker invites all participants to contribute their thoughts and ideas by suggesting they write down some thoughts.",
            "clarify goal": "The speaker clarifies the goal of the discussion by specifying the topic of metabolites and suggesting potential discussion points."
        }
    },
    {
        "utterance": "Jin Zhang: Can aptamers and other probes be developed for this? Uh those are the three um topics uh you know sort of initially posed. Posted. Um so okay, one minute start now. ",
        "annotations": {
            "ask question": "Jin Zhang explicitly asks if aptamers and other probes can be developed for this, seeking information.",
            "develop idea": "Jin Zhang elaborates on the topics initially posed.",
            "process management": "Jin Zhang instructs the group to take a minute to write down their thoughts, managing the meeting process."
        }
    },
    {
        "utterance": "Jin Zhang: All right, I think that's it. Um feel free to refer to that these notes um or um if there's a pause maybe Matt or I will ask you to read from your notes. Uh so Matt, you can take over for the intro now. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by indicating the completion of one task and transitioning to another.",
            "None": "No other code seems directly applicable as the primary function is process management."
        }
    },
    {
        "utterance": "Matt Bogyo: Yeah, sure. Um Molly's done eating so we can go back to Molly. ",
        "annotations": {
            "supportive response": "Matt Bogyo is expressing agreement with Jin Zhang's suggestion to proceed with the discussion.",
            "encourage participation": "By mentioning Molly, Matt Bogyo is inviting her to contribute to the discussion."
        }
    },
    {
        "utterance": "Molly Bright: I know. Coffee's coming. Um yeah, I'm Molly Bright. I'm at Northwestern in Chicago. ",
        "annotations": {
            "signal expertise": "Molly mentions her name and affiliation, which can be seen as subtly signaling her background or expertise.",
            "express humor": "Molly makes a light comment about coffee coming, which can be considered an attempt to express humor."
        }
    },
    {
        "utterance": "Molly Bright: Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Kevin Cash: Kevin Cash from Colorado School of Mines and my lab makes nanoparticle based sensors and one of our key applications is measuring oxygen dynamics in a range of microbial and in vivo systems as a proxy for metabolism. ",
        "annotations": {
            "signal expertise": "Kevin explicitly states his background and his lab's work, indicating his expertise."
        }
    },
    {
        "utterance": "Kevin Cash: So rather than measuring a wide suite of things, we measure oxygen and say, well, that's a good proxy for what's going on and use that to look at spatial and temporal dynamics. ",
        "annotations": {
            "develop idea": "The utterance expands on Kevin Cash's previous statement about his lab making nanoparticle-based sensors for measuring oxygen dynamics, providing more details on their approach.",
            "signal expertise": "Kevin Cash is explicitly stating his lab's expertise and approach in measuring oxygen dynamics."
        }
    },
    {
        "utterance": "Matt Bogyo: Okay, great. ",
        "annotations": {
            "supportive response": "Matt Bogyo is expressing agreement or validation with Kevin's introduction.",
            "acknowledge contribution": "Matt Bogyo is verbally recognizing Kevin's input."
        }
    },
    {
        "utterance": "Matt Bogyo: How about uh Sue? Sue, I guess. ",
        "annotations": {
            "encourage participation": "The speaker directly addresses Sue and invites her to contribute, fitting the definition of encouraging participation."
        }
    },
    {
        "utterance": "Seu Sim: Hello. So I'm an assistant professor in chemistry at UC Irvine and I'm a soft matter chemist, meaning I engineer polymers and proteins with living cells. So I'm currently interested in organizing bacterial communities within three dimensional mesh or 3D printed architectures and understand their dynamics and interactions. ",
        "annotations": {
            "signal expertise": "Seu Sim explicitly states their own expertise as an assistant professor in chemistry at UC Irvine and describes their work as a soft matter chemist."
        }
    },
    {
        "utterance": "Seu Sim: Nice to meet you all. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance as it serves a general social greeting function without explicitly introducing new ideas, asking questions, providing feedback, or directly managing the meeting process."
        }
    },
    {
        "utterance": "Matt Bogyo: Okay uh Candace. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by moving on to the next person for their introduction."
        }
    },
    {
        "utterance": "Candace Fleischer: Hi, I'm Candace Fleischer at Emory. Uh my lab primarily does in vivo MR spectroscopy and thermometry of the human brain. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise and qualifications related to the task, mentioning her name, affiliation with Emory, and the focus of her lab."
        }
    },
    {
        "utterance": "Matt Bogyo: Uh Alex. ",
        "annotations": {
            "encourage participation": "Matt Bogyo is inviting Alex to contribute by calling their name, indicating it's their turn to speak or share their thoughts."
        }
    },
    {
        "utterance": "Walsh, Alex: Hi, I'm Alex. I'm at Texas A&M University and I do optical imaging of mostly fluorescence and fluorescence lifetime of NADH and FAD. So those are molecules used in metabolic processes. So we're um able to to image something about metabolism that way. ",
        "annotations": {
            "signal expertise": "Alex explicitly states his own expertise or qualifications related to the task by mentioning his work on optical imaging."
        }
    },
    {
        "utterance": "Matt Bogyo: Uh Allison. ",
        "annotations": {
            "encourage participation": "The speaker, Matt Bogyo, is directly addressing Allison, inviting her to contribute or introduce herself, which encourages participation."
        }
    },
    {
        "utterance": "Allison Dennis: Hi, I'm Allison Dennis. I'm at Boston University. I um work on fluorescence sensors and fluorescent imaging contrast agents and one of the things that projects that seems most relevant to this uh discussion is we have some small molecule fret sensors that use allosteric transcription factors to bind and unbind DNA in response to a small molecule being around. So if there were favorite transcription factors for metabolites that would be something we'd be interested in making sensors for for example. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states their background and work at Boston University.",
            "develop idea": "The speaker elaborates on their work on fluorescence sensors and its relevance to the discussion.",
            "ask question": "The speaker asks if there are favorite transcription factors for metabolites."
        }
    },
    {
        "utterance": "Allison Dennis: Thanks. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Matt Bogyo: All right, great. Ping. ",
        "annotations": {
            "supportive response": "The speaker expresses agreement or acknowledgment with 'All right, great'.",
            "None": "No other relevant code applies to this utterance as the primary function is a brief acknowledgment and a call for someone's attention."
        }
    },
    {
        "utterance": "Ping Wang: Hi, um I'm Ping Wang, um assistant professor in radiology from uh Michigan State. Um I I was trained as interventional radiologist and uh develop uh interest in molecular imaging um of diabetes. Uh so the research work in my lab uh mainly focus on uh using imaging uh matters to track the transplanted uh human islet uh and also the stem cell differentiate islet organoids. Um we also uh work a little bit on the nano drug delivery to the targeting the endogenous beta cells. Uh the imaging modality uh we uh use often uh include uh MRI, uh pet MRI um and uh we use the optical imaging um system all the time. Um now uh we have been studying using um magnetic particle imaging. Uh looking forward to have the um discussions with all of you. ",
        "annotations": {
            "signal expertise": "The speaker explicitly states his own expertise and qualifications, mentioning his position as an assistant professor in radiology from Michigan State and his background as an interventional radiologist.",
            "develop idea": "The speaker elaborates on his research work, focusing on molecular imaging of diabetes, tracking transplanted human islet, stem cell-differentiated islet organoids, and nano drug delivery."
        }
    },
    {
        "utterance": "Matt Bogyo: Great, Catherine. ",
        "annotations": {
            "None": "No relevant code specifically applies to this brief acknowledgment utterance."
        }
    },
    {
        "utterance": "Katharine White: Hi, I'm Katherine White. I'm an assistant professor at the University of Notre Dame and my lab sits at the interface between chemical biology and and cancer cell biology. We develop new optogenetic tools that allow us to manipulate intracellular pH in single cells in real time. Um and as it relates to the kind of concepts here, we're interested in understanding how pH dynamics affect proteins, pathways, cell behaviors and we have some really interesting data uh linking initial pH changes with with metabolic reprogramming that we would like to better understand the dynamics of of that cross talk. So ",
        "annotations": {
            "signal expertise": "The speaker explicitly states her own expertise and qualifications related to her research.",
            "develop idea": "The speaker elaborates on her research area, explaining what her lab does and their interests."
        }
    },
    {
        "utterance": "Katharine White: Great. ",
        "annotations": {
            "supportive response": "Expressing agreement or positive evaluation.",
            "acknowledge contribution": "Verbally recognizing the previous speaker's input."
        }
    },
    {
        "utterance": "Matt Bogyo: Thanks uh Lou. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a simple expression of gratitude without any substantial content related to the discussion or meeting process."
        }
    },
    {
        "utterance": "Lu Wei: Hi, I'm Lou. Um um I'm assistant professor of chemistry at Caltech. Um so we work on um broadly vibrational uh spectroscopy and and microscopy uh mostly currently on on stimulate Raman. ",
        "annotations": {
            "signal expertise": "The utterance explicitly states Lu Wei's own expertise or qualifications related to the task, which is in the field of chemistry, specifically vibrational spectroscopy and microscopy."
        }
    },
    {
        "utterance": "Lu Wei: Um so we are actually trying to push Rama into a um uh well Raman guided uh spatial metabolomics platform. Um so on a single cell level we're trying to um connect the dots, uh draw the correlation between Rama measurements on both spectroscopy and imaging side to uh single ",
        "annotations": {
            "propose new idea": "The speaker introduces their work on using Raman guided spatial metabolomics platform.",
            "develop idea": "The speaker elaborates on their approach to connect Raman measurements on both spectroscopy and imaging sides."
        }
    },
    {
        "utterance": "Lu Wei_Caltech: cell transcriptomics, um, uh, and also the mass spec, uh, measurement on the on the bulk level. Um, on the, uh, specially resolved level, we're trying to identify new signatures from Raman and trying to, um, resolve the metabolic control, um, um, um, for disease systems. So, uh, recently we, uh, we're trying to identify, um, the metabolic system abilities during, uh, the development of drug resistance in, uh, melanoma patients. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on their existing research approach, explaining how they are using Raman spectroscopy to study metabolic systems and disease.",
            "propose new idea": "The speaker is implicitly suggesting a new approach by combining Raman measurements with cell transcriptomics and mass spectrometry to understand metabolic control in disease systems.",
            "signal expertise": "The speaker is explicitly stating their own expertise in the field of vibrational spectroscopy and its applications."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Great. Uh, Lingyan. ",
        "annotations": {
            "process management": "This code applies because Matt Bogyo is managing the meeting flow by transitioning to the next participant's introduction."
        }
    },
    {
        "utterance": "Lingyan Shi: Hi, um, my name is Lingyan Shi. I'm an assistant professor in UCSD at the bioengineering department. Our my lab is developing optical imaging techniques such as SRS and multifoton fluorescence microscopy. So we have been integrating two imaging modalities together to visualize the metabolic activities in living living organisms. So there are two layers of of imaging approach. One is the label free including the fluorescence multifoton fluorescence for example, we look at the NADH or flavor molecules in the living organism. And another layer is the Raman label free approach that we can visualize those lipids and protein information inside the animals and tissues. And we also want to separate the new molecules, uh newly synthesized molecule from the older endogenous molecules. So we have been also label those metabolites such as using heavy water or deterium labeled glucose amino acids to probe the metabolic activities in the live animals. So uh in that case we can separate those new molecules from the older molecules and uh quantitatively image the metabolic turnover rate for each of the macro molecules in the in the body. And uh very glad to discuss with you all today. Thank you. ",
        "annotations": {
            "develop idea": "The speaker expands on her lab's work, detailing the optical imaging techniques such as SRS and multifoton fluorescence microscopy, and their applications in visualizing metabolic activities."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Great. That's a good group. I think we have a lot of people working on metabolites, also tons of different modalities and different approaches to imaging, which so it should be a good discussion. Um, I mean, I guess to kick it off, we could start with the sort of first prompt, which I thought was kind of interesting is the idea of metabolites being a sort of early stage, um, reporter for bigger biological processes. So can they be used for diagnostic purposes and um, maybe that would be a good place to start if people have some ideas about that topic. ",
        "annotations": {
            "propose new idea": "The speaker introduces the idea of exploring metabolites as early-stage reporters for bigger biological processes.",
            "ask question": "The speaker asks if metabolites can be used for diagnostic purposes.",
            "encourage participation": "The speaker invites others to share their ideas on the topic."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: And I might broaden it out a bit to rather than just like measuring the metabolic things directly, do patterns in it change, do um, variability in measurements change, like what other things can we use that might be diagnostically relevant before we see physiological impacts. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the existing idea of using metabolites for diagnostic purposes by suggesting to look into patterns and variability.",
            "ask question": "The speaker is requesting information or suggestions from others on what other things might be diagnostically relevant."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah, that actually sort of uh um is related to uh one of the uh things that mentioned by different people. I think in terms of looking at metabolites uh or metabolic processes uh what I guess what are the targets, the variety of different targets that we're we're thinking about. I I guess uh summarizing different, you know, different people's uh intro, uh, you know, we looked at uh newly synthesized metabolites as a sort of a whole class, uh specific species, um, NADPH, NADH, uh or oxygen uh as a proxy or or uh developing specific probes for a very specific metabolite. So uh there these are all possibilities. What are some of the advantages uh and challenges uh of targeting these different things for looking at metabolites and metabolic processes. And as Kevin mentioned, uh perhaps, you know, patterns, uh features of any of those, right? as a you know, class uh or as a individual species could be used for diagnostic purpose. Just to uh throw the question out there. ",
        "annotations": {
            "develop idea": "Jin Zhang is expanding on existing ideas by suggesting considering various targets for metabolites and discussing their advantages and challenges.",
            "ask question": "Jin Zhang explicitly asks for the advantages and challenges of targeting different metabolites or metabolic processes, which is a clear request for information."
        }
    },
    {
        "utterance": "Katharine White - Notre Dame: I can talk about if um, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lingyan Shi: May I may I say something about the newly synthesized one with labeling? ",
        "annotations": {
            "ask question": "Lingyan Shi is requesting to discuss or provide information about a specific topic, which implies a question about the appropriateness or relevance of her contribution."
        }
    },
    {
        "utterance": "Lingyan Shi: to break the diffraction limit limitation to have a better spatial resolution. ",
        "annotations": {
            "clarify goal": "The utterance clarifies a goal to have better spatial resolution by addressing the diffraction limit limitation.",
            "identify gap": "The utterance implicitly identifies a gap in current capabilities, which is the limitation imposed by the diffraction limit."
        }
    },
    {
        "utterance": "Katharine White: Yeah, I just wanted to if I can add on onto that because I think you brought up a lot of really interesting points there. Uh, one of which is this kind of spatial resolution of metabolism and so, you know, a lot of the approaches that we have on the cell biology side in terms of, you know, broad population level metabolomics are not sufficient for a lot of the questions that apparently everyone in this group is is similarly thinking about in terms of the spatial organization in 3D and in a tissue where oxygen gradients, pH gradients, nutrient availability might be very altered and so this this ability to get it at spatial organization of metabolism within a cell, within tissue, within an organism I think is is really important and we need to think about the the needs there and then um, you know, I I think it's fascinating that you want subpixel um information there. That is just blows my mind because we can't even get, you know, reasonable dynamic measurements in a single cell sometimes and so the idea that you could have that kind of of uh resolution is is really interesting to me. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by discussing the importance of spatial resolution in metabolism.",
            "identify gap": "The speaker mentions a gap in current approaches regarding spatial organization and measurement resolution."
        }
    },
    {
        "utterance": "Katharine White: Um, but I think coming this connects also to to Kevin's point about heterogeneity and uh at the, you know, uh what is the variability that we're interested in and and what is the sensitivity that we need in our measurement tool to be uh confident that we're capturing that variability if it's biologically meaningful. ",
        "annotations": {
            "develop idea": "Katharine White is expanding on Kevin's point about heterogeneity by introducing the concept of variability and sensitivity in measurement tools.",
            "ask question": "Katharine White is requesting information about the variability of interest and the sensitivity needed in measurement tools."
        }
    },
    {
        "utterance": "Katharine White: And as as we come at this problem, we see a lot of these correlations at the population level that we're not able to confirm at a single cell level reliably. And so one of the uh questions that maybe we can kind of jump off of where Kevin uh and Lingyan got us started is, you know, what are the constraints there? What is the what is the need in terms of probes in terms of to make these kind of leaps from maps or measurements to diagnosis to phenotype to um outcome. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas by discussing the limitations and challenges of studying correlations at different levels.",
            "ask question": "The speaker is requesting information about the constraints and needs in terms of probes for further understanding."
        }
    },
    {
        "utterance": "Seu Sim: So I I make polymers. So I something that I wrote down here. I I love the idea of using mass spectrometry to look at the metabolomic processes, but as many of you pointed out, it's a very small scale problem. So we can also imagine using expansion microscopy, but then you have to think of a way to anchor your molecules of interest in a reliable way so that it flies. So have anyone, you know, read anything about it and, you know, any experiences I would love to talk about it. ",
        "annotations": {
            "propose new idea": "Seu Sim suggests using expansion microscopy as an alternative approach to mass spectrometry for looking at metabolomic processes.",
            "develop idea": "Seu Sim elaborates on the idea of using expansion microscopy and mentions a challenge related to anchoring molecules of interest.",
            "ask question": "Seu Sim asks for input or experiences from others regarding the suggested approach."
        }
    },
    {
        "utterance": "Matt Bogyo: So do do people know currently for like what's I mean, I know mass spec is being used as an imaging technique and that's good for small metabolites, but um obviously it has limitations because you have to process samples in a very specific way. Um yeah, I guess the question is, you know, how do you integrate those technologies into something that's a reasonable diagnostic workflow for for like a clinical specimen or are we talking about samples that would be biopsied or where where do you guys see the application in metabolic profiling? ",
        "annotations": {
            "ask question": "The speaker is requesting information on integrating technologies into a diagnostic workflow for clinical specimens or biopsied samples.",
            "develop idea": "The speaker is building upon previous discussions about mass spec's use in imaging small metabolites and its limitations."
        }
    },
    {
        "utterance": "Lingyan Shi: Well, um yes, I think one application is already uh being conducting in hospital with SRS, the stimulated Raman microscopy is to uh really separate those cancer cell from the normal normal tissue. For example, the the brain tumor case. So for the brain tumor removal, the surgeon will just take take out the just open the skull and take out the brain tumor and they usually will do assess on that uh scar wall inside the brain to to see if there's any tumor cell left inside the brain. So the traditional or conventional way is to just take a little very little tiny piece out and do the histology image H and E staining to to check if the cell uh are all brain cells and there's no tumor cells left inside. So then we can close the skull and wake up the patient. ",
        "annotations": {
            "develop idea": "The utterance provides a detailed example of how SRS (stimulated Raman microscopy) is being used in hospitals to separate cancer cells from normal tissue, specifically in brain tumor removal surgeries, thereby elaborating on an existing idea."
        }
    },
    {
        "utterance": "Lingyan Shi: But usually it takes the conventional method usually takes too long and uh maybe a few hours so that the patient will be under anesthesia for a few hours waiting for the results. But now um since SRS allow us to visualize the protein and the lipids very rapidly. Well for example I I I take like five minutes to take the image when you have that piece of tissue and immediately you have the digital H and E maybe H and E and the pathologist can look at the H image in a few minutes and determine if there's tumor still left or not. So it saves a few hours and uh the patient can be wake up very soon um not they they don't need to be under anesthesia for that long. So it's kind of protecting the brain. Also it's it's a biopsy. It's a it's a diagnostic biopsy um during the clinical clinical clinical period. So I think that types of like fast rapid diagnostic molecular level determination of based on the imaging technology such as SRS may uh be helpful. ",
        "annotations": {
            "develop idea": "The speaker is expanding on how SRS can be used for diagnostic imaging, providing examples and benefits.",
            "supportive response": "The speaker is expressing a positive view of SRS for diagnostic purposes, highlighting its benefits.",
            "clarify goal": "The speaker is discussing the goal of using SRS for rapid diagnostic molecular level determination."
        }
    },
    {
        "utterance": "Matt Bogyo: So what other types of modalities do you guys think would be useful? Obviously, so Raman is one, right, that we're just talking about. Are are other people here have expertise in other modalities that could be applied in the sort of clinical setting? And maybe also maybe we could think about some of the limitations to that strategy using Raman or ",
        "annotations": {
            "ask question": "Matt is explicitly asking for opinions and information from the group about other modalities and their limitations.",
            "encourage participation": "Matt is explicitly inviting others to contribute their expertise and opinions."
        }
    },
    {
        "utterance": "Ping Wang: I I just want to add a little bit to the discussion. Um, for the um, for the first question, um, metabolic change, uh, I mean, use metabolic imaging used for diagnostically. If you include cancer, um, like I mean, as as a disease for for like a cancer metabolic imaging as part of the discussion, I think it's already been widely used. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of using metabolic imaging for diagnostic purposes, specifically mentioning its application in cancer.",
            "offer feedback": "The speaker is providing insights into the use of metabolic imaging in diagnostics, particularly in cancer, which can be seen as a form of feedback to the discussion.",
            "clarify goal": "The speaker's contribution helps in clarifying or expanding the goals of the discussion, specifically by highlighting the use of metabolic imaging in cancer diagnostics."
        }
    },
    {
        "utterance": "Ping Wang: I mean, it's a clinical modality. I mean, pet I uh especially for pet like FDG uh F18 FDG, that's widely used every day for the diagnosis. Um, and for another disease I have been working on for diabetes, um, yeah, it's it's closely to the glucose metabolism. ",
        "annotations": {
            "Develop idea": "The speaker is elaborating on the idea of using PET for diagnostic purposes, specifically mentioning its application in cancer diagnosis and diabetes.",
            "Signal expertise": "The speaker is sharing their knowledge or experience with PET and its applications, indicating their expertise in the area."
        }
    },
    {
        "utterance": "Ping Wang: Uh so um in terms of diabetes um there's a there's a very big problem for us like for the endogenous beta cell imaging, beta cell mass imaging. That's a very big problem and people trying to solve this problem for 20 years still not successful. Um because of limited uh special resolution and also the sensitivity we use. We have been tried with the MRI mostly and some people tried pet. So that's why people trying to uh combine the pet MRI uh to complement each other to increase the uh sensitivity and the special resolution. Um in creating um like receptor imaging also it's a big big part for the metabolic imaging. Um example for that is the GLP1 glucagon like peptide one. Um that's also related to the beta cell imaging. ",
        "annotations": {
            "identify gap": "The speaker highlights a significant challenge in diabetes research, specifically the difficulty in imaging endogenous beta cells and beta cell mass despite 20 years of effort.",
            "acknowledge contribution": "The speaker acknowledges previous work and efforts by others in trying to solve the problem of beta cell imaging.",
            "develop idea": "The speaker discusses potential solutions, including the combination of PET and MRI, and the role of receptor imaging in metabolic imaging for beta cell imaging."
        }
    },
    {
        "utterance": "Ping Wang: I do have another I do have a question for Kevin. to for for my uh experiment. ",
        "annotations": {
            "ask question": "The speaker, Ping Wang, is requesting information from Kevin related to their experiment."
        }
    },
    {
        "utterance": "Ping Wang (MSU): uh the lack of oxygen, um and lack of the blood supply um is may contributors for this um eyelid organoids uh graphs um loss. ",
        "annotations": {
            "identify gap": "The speaker is explicitly recognizing potential contributors (lack of oxygen and blood supply) to the loss of eyelid organoids, indicating gaps in current control or understanding.",
            "offer feedback": "The speaker provides a possible explanation for the observed loss of organoids, suggesting factors that could be contributing to this issue."
        }
    },
    {
        "utterance": "Ping Wang (MSU): So um if if you can comment on that um like if we can label the cells with some nanoparticles uh you you design synthesize as an indicator uh for the oxygen um I mean level uh in the transplant sites. ",
        "annotations": {
            "ask question": "The speaker is requesting information on using nanoparticles as indicators for oxygen levels in transplant sites."
        }
    },
    {
        "utterance": "Ping Wang (MSU): That's probably uh one I mean application for clinic because you know in clinic for eyelid transplantation for type one diabetes um one recipient usually need two donors, the eyelid from two donors. And uh the clinical data showed nowadays like less than 50% of the recipients um can remain independent uh insulin independence after five years. So ",
        "annotations": {
            "identify gap": "The speaker highlights a challenge in the field of eyelid transplantation for type one diabetes patients, where less than 50% of recipients can remain insulin-independent after five years.",
            "clarify goal": "The speaker discusses a specific application and challenge in metabolic imaging, relating to improving outcomes for eyelid transplantation in type one diabetes patients."
        }
    },
    {
        "utterance": "Ping Wang (MSU): we trying to develop something like uh maintain the function of the eyelid uh graphs. ",
        "annotations": {
            "clarify goal": "The speaker is defining their objective, which is to maintain the function of eyelid grafts, indicating a clarification of what they are trying to achieve."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: I mean at least for our technology in particular, ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: it likely wouldn't work because our stuff's all optical. So if it's actually transplanted into a patient, uh it's not optically accessible anymore. ",
        "annotations": {
            "identify gap": "The speaker explicitly recognizes a limitation of his technology in being optically accessible when transplanted into a patient.",
            "offer feedback": "Kevin provides specific information about the limitations of his technology for a particular application."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: But I'm sure there's other oxygen sensitive approaches that would work in that deeper tissue. ",
        "annotations": {
            "supportive response": "The speaker is providing a positive, supportive comment by suggesting alternative approaches.",
            "offer feedback": "The speaker is providing a suggestion or an alternative approach."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: But just the the ones we do are all optical because for us we're doing most of our stuff either near surface or in in vitro model systems. ",
        "annotations": {
            "None": "The utterance provides specific information about the limitations of their technology without proposing new ideas, asking questions, or engaging in discussions that fit the other categories."
        }
    },
    {
        "utterance": "Ping Wang (MSU): Yeah, some uh developed for the optical imaging can um also can be considered like radio labeled, yeah, for para paramize. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new suggestion about considering optical imaging techniques that can also be radio-labeled.",
            "offer feedback": "The speaker provides a suggestion or idea for how to approach the discussed challenges."
        }
    },
    {
        "utterance": "Ping Wang (MSU): Okay. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: So what are some of the, I mean I'm just starting to think do people know I I don't keep up with as much about the metabolism imaging field, but I know like FDG is a big one, right? But that's just that's basically uptake of a reporter molecule by cancer cells. ",
        "annotations": {
            "ask question": "Matt is requesting information about the metabolism imaging field and its applications or methods.",
            "develop idea": "Matt is elaborating on existing ideas by mentioning and explaining FDG's role in metabolism imaging."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: But are there other classes of like contrast agents for example that that bind or that are mimics of metabolites and that accumulate much like FDG so that are used in other areas? Seems like that's another area that would be important. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the existence of other classes of contrast agents that mimic or bind to metabolites, similar to FDG, and their applications in other areas.",
            "identify gap": "The question implies a gap in the speaker's knowledge about contrast agents that are used in similar contexts to FDG for metabolite imaging."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Yeah, I can talk briefly about MR spectroscopy, which I'm guessing most of you are familiar with, but it it is a marker of um or it is a method that can measure, you know, quantitative metabolite concentrations localized in whatever region. And it is used in the clinic, cancer is a good example, it's used for um like fatty liver disease. Um, but you do get like basically you get in vivo MR spectra um localized. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of MR spectroscopy, its capabilities, and applications.",
            "signal expertise": "The speaker is sharing her knowledge about MR spectroscopy, indicating her expertise in the area."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: It's also sampling error, right? I mean because you have to know where you want to look, right? ",
        "annotations": {
            "critical response": "Matt points out a limitation of the approach by mentioning 'sampling error', indicating a potential flaw in the methodology being discussed."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Yeah, I mean we can do whole brain, you can do multiple regions. I guess um yeah, I mean in a clinical setting you would do a small region of interest. Um so you'd have some information already. Um but I guess in terms of the bigger question of metabolism, you know, um something that is kind of emerging is genetic counseling. So using, you know, gene mutations to predict disease. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea of using MR spectroscopy for metabolic imaging, discussing the practicality of different approaches in clinical settings.",
            "identify gap": "The speaker hints at the challenges in directly measuring metabolites and suggests genetic counseling as an emerging alternative approach."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): And I guess the idea that I had with metabolic imaging is really, you know, we're not looking at kind of metabolism reprogramming, which we know is really common in cancer, but it's actually probably related to a number of different diseases, diabetes like Ping was saying. And so thinking about the very big picture is, you know, genetics are what we always go to for everything, right? ",
        "annotations": {
            "develop idea": "The speaker expands on the concept of metabolic imaging and its applications to various diseases.",
            "supportive response": "The speaker expresses a positive and engaging view towards exploring metabolic imaging for various diseases."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Cancer, do some genetics tests. Um children do some sort of genetic screening, etc, etc. But metabolism is often left out and we know like the prompt is saying, we know that metabolic changes can actually proceed any physiological or structural changes. So from a very big picture, imaging metabolism with maybe in the clinic with the exception of FDG pet and some other tracers from mostly cancer, right? ",
        "annotations": {
            "develop idea": "The speaker is expanding on the concept of metabolic imaging and its potential, building upon the previous discussion.",
            "identify gap": "The speaker implies a gap in the current clinical practice, specifically that metabolism is often left out of diagnostic approaches.",
            "supportive response": "The speaker is expressing agreement with the importance of metabolic imaging."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Um is is pretty absent. And so I think there is a big need for thinking about this on a very large scale in terms of, you know, why is metabolism important? Is it important? How is it important? Um and obviously with something like MRI we're working on a very macroscopic scale like you said, we have large regions. ",
        "annotations": {
            "Ask Question": "The speaker is asking questions about the importance of metabolism, seeking information or clarification.",
            "Develop Idea": "The speaker is elaborating on the idea that metabolic considerations are absent and discussing its implications.",
            "Clarify Goal": "The speaker's questions aim at understanding why and how metabolism is important, which relates to clarifying goals or objectives."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): So is MRI done like pretty routinely now like for for metabolic imaging in cancer? ",
        "annotations": {
            "ask question": "The speaker is requesting information about the routine use of MRI for metabolic imaging in cancer, seeking clarification or expertise from other team members."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Like I mean it does it does seem like it requires a lot of time and instrumentation and cost and other things. I mean are there barriers there? ",
        "annotations": {
            "ask question": "The speaker is requesting information about potential barriers or challenges in using certain imaging modalities in clinical settings.",
            "identify gap": "The speaker is highlighting potential limitations or gaps in implementing MRI for metabolic imaging, specifically mentioning time, instrumentation, cost, and other things."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Um, I mean it it I would say in many clinics it is done routinely. Um it it depends a little on the tumor, but it's the exact same instrumentation and anytime someone has a tumor you would scan them with an MRI anyway. So they're already in the scanner if you allow if your site does spectroscopy, ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and a positive evaluation of the routine use of MRI for metabolic imaging in cancer in many clinics."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): it's it's naturally integrated into every MRI whether you use it or not. You you kind of have to pay extra for it when you're buying your system. So if you didn't do that you won't have it. But um even non-academic sites are using spectroscopy for tumors. Um so I wouldn't say it's routine, but I would say for so for example for fatty liver disease it is routine because that's a really great way to quickly sample fat distribution. ",
        "annotations": {
            "develop idea": "The utterance expands on the idea of using spectroscopy in MRI for clinical purposes, specifically mentioning its use in tumor assessment and fatty liver disease.",
            "supportive response": "It provides a positive evaluation of using spectroscopy for certain applications, like fatty liver disease."
        }
    },
    {
        "utterance": "Candace Fleischer (Emory, she/her): Yeah. Cool. ",
        "annotations": {
            "Supportive response": "The utterance expresses a positive sentiment towards the conversation, which can be seen as a form of agreement or validation."
        }
    },
    {
        "utterance": "Lu Wei, Caltech: So following up on that, I actually I'm interested to understand some of the technical challenges across different modalities. ",
        "annotations": {
            "ask question": "Lu Wei is seeking information or clarification on the technical challenges across different modalities discussed previously."
        }
    },
    {
        "utterance": "Lu Wei, Caltech: So for example, Candace you just said uh for MRI um to do metabolic imaging, what are the I mean for from a technical point of view, what are the challenges that limits is for the applications? What are the issues you usually run into? ",
        "annotations": {
            "ask question": "The speaker is requesting information about the technical challenges of MRI in metabolic imaging, making this code applicable."
        }
    },
    {
        "utterance": "Lu Wei, Caltech: So for example for us, um I I guess for for for FDG for pet in order to overcome those fast decay, you have to prepare the sample very fast and then you only have a limited window to do the imaging. Um for us for Rama, we have the corresponding uh deuterium version of glucose or alcohol version of glucose that we can image. Uh which worked very well at a relatively longer time scale, um but uh with a shorter time scale, for example on the minutes or uh tens of minutes level where I usually limited by uh the sensitivity. So we don't have we don't have enough molecule accumulated for detection. ",
        "annotations": {
            "develop idea": "The speaker is elaborating on existing ideas by explaining the challenges with FDG for PET and Raman spectroscopy, providing examples of how they work.",
            "identify gap": "The speaker is highlighting limitations and challenges, indicating gaps in current capabilities, particularly in terms of sensitivity and time scales for imaging."
        }
    },
    {
        "utterance": "Lu Wei, Caltech: And also um uh I I saw there's a question on um whether there's a aptamer uh based uh probes that could be developed to imaging metabolites. ",
        "annotations": {
            "ask question": "The speaker is asking for information about the possibility of developing aptamer-based probes for imaging metabolites, referring to a previous question."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Great questions. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges Lu Wei's questions.",
            "supportive response": "The speaker expresses a positive evaluation of Lu Wei's questions."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): So do we want to start one you know, do one by one? ",
        "annotations": {
            "process management": "The speaker is suggesting a method to organize their discussion or task, proposing to handle items one by one."
        }
    },
    {
        "utterance": "Lu Wei, Caltech:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): You Candace, you want to um answer uh uh ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): the question about the the limitation I guess I I also have related the question whether for the MRI metabolic imaging this is looking at fat, right? And uh and uh are there uh you know, you know, limitations what um uh was asking. but in terms of uh expanding it, you know, is there a need for metabolic profiling for looking at um more uh or or more specific species of metabolites and things along that line. ",
        "annotations": {
            "ask question": "The speaker is requesting information about the limitations of MRI metabolic imaging and the need for metabolic profiling.",
            "develop idea": "The speaker is expanding on the discussion about metabolic imaging, its limitations, and potential applications."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): And then I'll come back to the uh buffering problem of a probe based. ",
        "annotations": {
            "process management": "The speaker is managing the discussion flow by indicating a desire to return to a previous topic."
        }
    },
    {
        "utterance": "Candace Fleischer: um, you know, hydrogen nuclei, which is are present in everything. Um, so I think those are the pros, but it's certainly challenging. And then, you know, on the other side of things, the analysis is difficult. So while there's some inline analysis, so you know, a radiologist can sit at the scanner and see peaks and get approximate idea of patterns. Um, it's not 100% quantitative, it's not standardized across sites. Um, I guess that's those are big medical imaging questions separately even from metabolism is um, are those limitations. ",
        "annotations": {
            "critical response": "The speaker is discussing the limitations and challenges of MRI for metabolic imaging, highlighting the difficulties in analysis and lack of standardization.",
            "offer feedback": "The speaker is providing specific comments on the challenges and limitations of MRI for metabolic imaging, offering feedback on its current state and potential improvements."
        }
    },
    {
        "utterance": "Jin Zhang: Well, I guess related to that, there perhaps um, there isn't a need to really look at very, very specific species, right, in that setting. Just uh looking at overall perhaps, you know, phospho phosphorus um or or fat signal, um you don't have to really look at a one particular lipid species. That's my question related to the MRI. ",
        "annotations": {
            "develop idea": "Jin Zhang is expanding on previous ideas about metabolic imaging, discussing the practicality of focusing on specific versus overall metabolite signals.",
            "ask question": "Jin Zhang explicitly asks for thoughts or opinions on the necessity of looking at specific metabolite species versus overall signals in MRI settings."
        }
    },
    {
        "utterance": "Candace Fleischer: You don't have to, but I would say most people do. ",
        "annotations": {
            "develop idea": "Candace is expanding on the idea of using MRI for metabolic imaging by suggesting that while it's not necessary to look at very specific species of metabolites, most people do so in practice.",
            "supportive response": "Candace is expressing a positive evaluation of the approach by indicating that most people look at specific species, thereby supporting the idea that specificity can be important."
        }
    },
    {
        "utterance": "Jin Zhang: Sorry. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Candace Fleischer: I said you don't have to, but most people do. So, for example, in tumors, um, you know, for Raman biopsy is one example, but we can also do that with MR spectroscopy and see the boundary of the tumor and actually we're using that in our clinic to guide radiation therapy. ",
        "annotations": {
            "develop idea": "The speaker expands on a previous idea about using MR spectroscopy for tumor analysis, providing a concrete example of its application in guiding radiation therapy.",
            "offer feedback": "The speaker offers feedback on the practical application of MR spectroscopy in a clinical setting, highlighting its utility."
        }
    },
    {
        "utterance": "Candace Fleischer: Um so we can take an image and see areas that were weren't resected given metabolic ratios in the brain and then we can target those regions. Um, so you you're right, you certainly don't have to. It can be untarget kind of an untarget metabolomics approach. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas about using metabolic imaging for diagnostics and therapy by providing specific examples of its application.",
            "offer feedback": "The speaker provides an alternative approach ('untarget kind of untarget metabolomics approach'), which can be seen as offering feedback on how to proceed with metabolomics."
        }
    },
    {
        "utterance": "Candace Fleischer: . ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang: So come back coming back to um, Lou's question about the uh uh is it Lou or Way? Sorry. ",
        "annotations": {
            "express humor": "The speaker makes a light, humorous comment about possibly mispronouncing a name, which is an attempt to make a joke or diffuse any potential awkwardness."
        }
    },
    {
        "utterance": "Lu Wei: Lou, Lou. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lu Wei: Unmuted. It's Lou, yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang: Lou, okay. Lou's question about um the uh um buffering effect. ",
        "annotations": {
            "acknowledge contribution": "Jin Zhang acknowledges Lou's question about the buffering effect."
        }
    },
    {
        "utterance": "Jin Zhang: Um so this you know, of course uh if we design optical probe or or some of the other probes to to um bind to a specific molecule or uh you know, replace that endogenous molecule with a labeled molecule. Uh there there's uh you know, unwanted effect um uh like a buffering effect uh or or perturbation effect. But I guess the idea is um if you can really enhance the sensitivity and to, you know, to use that as a tracer, right? That's kind of the the pet um imaging that's what the based on, you know, you can really enhance the sensitivity lower the the amount of labeling. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing concepts of probe design and imaging techniques, elaborating on challenges and potential solutions.",
            "identify gap": "The speaker mentions potential unwanted effects (buffering effect or perturbation effect), which implies identifying a challenge or gap in current methods.",
            "offer feedback": "The speaker provides some form of feedback on the idea of using probes as tracers."
        }
    },
    {
        "utterance": "Jin Zhang: Then you're uh going to the the sweet spot of um be able to detect something but not perturbing that much. Anyone want to chime in? I think Axon develop probes for uh along this line. Sorry, Sue was going to say something. ",
        "annotations": {
            "ask question": "The speaker is seeking input or opinions from others, indicated by 'Anyone want to chime in?'",
            "encourage participation": "The speaker is actively inviting others to contribute their thoughts or ideas, as seen in mentioning others and leaving space for their input."
        }
    },
    {
        "utterance": "Seu Sim: Oh, I was actually thinking in this domain. I I like the idea of aptamer based, but I also like the idea of like not just a binding event, something that's amplifiable so that we bring like the low concentration of metabolite into readable range. So in the spirit of lowest possible perturbation and something that's amplifiable, not just, oh, it it's bound to like A bound to B and that's definitely not going to be easy to detect. So I don't know if it's possible, but if we can think of it a way to, you know, bring this aptamer or nucleic acid based binding event and lead that into some amplification event so that we have dynamic range to read out rare metabolite that could be of interest can be an interesting direction. ",
        "annotations": {
            "propose new idea": "The speaker proposes using aptamer-based approaches with amplification for detecting metabolites.",
            "ask question": "The speaker questions the feasibility of bringing this aptamer or nucleic acid-based binding event into some amplification event."
        }
    },
    {
        "utterance": "Jin Zhang: Actually kind of contrary to the idea of having the amplification. ",
        "annotations": {
            "critical response": "The speaker expresses a contrary view to the idea of having amplification, indicating a critical perspective on the previously discussed approach."
        }
    },
    {
        "utterance": "Allison Dennis: I go back and forth on whether it's better to have or it's just application dependent, whether it's better to have that one snapshot with the amplification of signal, but then it's an an irreversible signal, right? You're always only increasing never, you know, playing with the the kinetics to have unbinding of the metabolite that you're you're sensing and and bringing the signal back down. So, you know, depending on the the uh dynamics of what the the molecule that you're trying to sense, it could be that you want that accumulation of signal um just to see it at all or you might want a a reversible signal so that you see the the uptick and then the the decline of the reduction in the concentration of that metabolite um in response to something. Just a a totally different design um for the two outcomes. ",
        "annotations": {
            "develop idea": "Allison discusses the merits and design considerations of having a snapshot with amplified signal versus a reversible signal in the context of sensing metabolites, elaborating on existing ideas."
        }
    },
    {
        "utterance": "Jin Zhang: Yeah, but perhaps for for different applications, uh that could, you know, the the different uh focuses or strategies. But I guess in principle, it is possible to build some amplification not for the binding part of it. ",
        "annotations": {
            "develop idea": "The speaker is expanding on existing ideas about strategies and possibilities for probe development in metabolic imaging, discussing different applications and feasibility."
        }
    },
    {
        "utterance": "Jin Zhang: Well, some simple applica amplification that you that's used by people in the field. Of course, there's enzymatic um amplification and um uh and there's transcriptional uh based. I think Andrew put it in the in the chat, ribo switch. ",
        "annotations": {
            "develop idea": "Jin Zhang is expanding on the concept of amplification by mentioning specific techniques like enzymatic and transcriptional-based amplification, which relates to the group's discussion on metabolic imaging and probe development."
        }
    },
    {
        "utterance": "Andrew Feig: Yeah, so consider um you might want to look at some of the systems that have been developed by the synthetic biology community, the gem circuits where you can they actually have modular circuits that are integrators for instance and uh that do uh uh timed phase as well. ",
        "annotations": {
            "encourage participation": "The speaker encourages the group to consider looking into systems developed by the synthetic biology community, suggesting exploration of new ideas and resources."
        }
    },
    {
        "utterance": "Andrew Feig: Well, so there there are a whole bunch of these that have been developed with uh different logics on circuits. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Right. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "The utterance is a minimal response and does not explicitly relate to any specific code provided."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "The speaker is simply acknowledging or agreeing with a prior statement without adding new content."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or validation."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "The utterance is a minimal response and does not explicitly fit into any other category provided in the codebook."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "The utterance is a minimal acknowledgment and does not explicitly fit any of the provided codes in a substantial way."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "The utterance is a simple acknowledgment without adding new content."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a minimal acknowledgment"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "acknowledge contribution": "The speaker is acknowledging a prior contribution or statement.",
            "supportive response": "The speaker is expressing agreement or validation."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "The utterance is a brief acknowledgment without adding new content or clearly fitting into another category."
        }
    },
    {
        "utterance": "Seu Sim: Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance as it is a very brief acknowledgment."
        }
    },
    {
        "utterance": "Candace Fleischer: products. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang: Great. Um, I wonder if Alex or Molly want to chime in for any of the topics, look at your notes. ",
        "annotations": {
            "encourage participation": "Jin Zhang invites Alex or Molly to contribute their thoughts or insights, encouraging participation in the discussion."
        }
    },
    {
        "utterance": "Molly Bright: And mainly I'm a little distracted. Sorry guys. Um, the yeah, I I'd say that with my type of MRI, we um, we say we want metabolism, but what we typically are saying is we want neural activity. And that's such a different thing and yet we say it and and that's sort of a mindset issue. Um, the other thing is out of the prompts that we started with, the idea that metabolic changes proceed physiological changes, I think when we're looking at the brain and and we are using physiological measures of um, well what I would call physiological measures, we're using vascular properties to estimate a metabolic property. So the timeline of things is really important when we try to infer one from the other. So in the pathologies, knowing when we can trust our models of how vascular signals relate to metabolism or when those models have already broken down because metabolism wrecked that something about the vascular thing we're measuring. I'm not sure I'm being very coherent, but I feel like it's it's a big challenge that like with a lot of things with this neuro MRI view of metabolism, I feel like we're we're a bit superficial with it so far. ",
        "annotations": {
            "develop idea": "Molly is expanding on the idea that metabolic changes and neural activity are often used interchangeably but are different, and discussing the challenges with using MRI for metabolic imaging.",
            "signal expertise": "Molly is sharing her perspective based on her experience with MRI.",
            "identify gap": "She mentions a challenge in trusting models of vascular signals relating to metabolism, implying a gap in current understanding or methods.",
            "express humor": "She makes a light comment about her coherence."
        }
    },
    {
        "utterance": "Molly Bright: Well metabolism, not MRS. I am not doing spectroscopy. ",
        "annotations": {
            "signal expertise": "Molly Bright is stating her expertise area by mentioning what she works on and what she does not.",
            "identify gap": "She is identifying a gap or distinction between her work on metabolism and other areas like MRS.",
            "clarify goal": "The utterance clarifies the focus of her work, distinguishing it from MRS and spectroscopy."
        }
    },
    {
        "utterance": "Molly Bright: Just to put that out there. That's a very different thing and much more interpretable. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Alex Walsh: Yeah, I think um, there's a lot of different things you can measure with metabolism, right? And uh, understanding the relationship between the molecules you're detecting and right your physiological outcome that you want to to actually know something about is is an important bridge that needs to be crossed. Um, so like when you do autofluorescence of NADH and FAD, we're very good at finding those molecules, but we're not so great at knowing what that tells us about metabolism. Um, and so I think that's that's the challenge for the field that I work in is trying to be more specific with things like metabolic pathways. ",
        "annotations": {
            "develop idea": "Alex Walsh is expanding on the idea that there's a lot to measure in metabolism and discussing the challenges in interpreting these measurements in terms of physiological outcomes.",
            "identify gap": "Alex points out a gap in knowledge regarding the interpretation of measurements of NADH and FAD in terms of metabolism."
        }
    },
    {
        "utterance": "Alex Walsh: So. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Matt Bogyo: Alex, can you expand on the limits of the using the endogenous fluorescence? ",
        "annotations": {
            "ask question": "The speaker is requesting information or clarification from another team member on a prior statement or idea proposed."
        }
    },
    {
        "utterance": "Allison Dennis: So you know how how thick of a tissue can you look at? Is it only monoculture? Can you look at spheroid? Yeah, what what's the scope can you. ",
        "annotations": {
            "ask question": "Allison Dennis is requesting information about the capabilities and limitations of the imaging technique, specifically regarding the types of samples that can be imaged."
        }
    },
    {
        "utterance": "Alex Walsh: Right. So it's it's just like normal fluorescence. So whatever techniques you use, it's it we can do it too. Um, so so we can do single photon and it's really great at looking at cells on a dish, but we can also adapt it for multiphoton and optical technologies that can do three-dimensional things like organoids or even in vivo up to a couple millimeters. ",
        "annotations": {
            "develop idea": "The speaker expands on existing ideas by explaining the applications and capabilities of single-photon and multiphoton technologies in biological imaging.",
            "clarify goal": "The speaker indirectly discusses objectives and outcomes by explaining how techniques can be used to achieve certain goals in biological research."
        }
    },
    {
        "utterance": "Matt Bogyo: I guess we should consider checking in with Kevin, seeing how uh how's things looking over there. Kevin, do we should probably pull together as a group and kind of summarize some of the main things we've been discussing so we have a sense of the report out. What do you think? ",
        "annotations": {
            "process management": "The speaker is suggesting a change in discussion flow by checking in with Kevin and proposing a summary of the main points discussed.",
            "summarize conversation": "The speaker explicitly mentions summarizing the main things discussed to have a sense of the report out."
        }
    },
    {
        "utterance": "Kevin Cash: Yeah, it's it's currently quite chaotic. ",
        "annotations": {
            "None": "No relevant code directly applies to this utterance, but it could be considered a minimal form of process management."
        }
    },
    {
        "utterance": "Matt Bogyo: Yeah, it's a little bit all over. Do you have um some notes or do you want to share screen or do you how do you want to do it? ",
        "annotations": {
            "process management": "The speaker is trying to manage the meeting flow by suggesting to organize the discussion.",
            "ask question": "The speaker is asking Kevin about his preference for proceeding with organizing the discussion."
        }
    },
    {
        "utterance": "Kevin Cash: Uh yeah, I can share the screen. ",
        "annotations": {
            "process management": "Kevin Cash is agreeing to share his screen, which can be seen as an action to manage the meeting process by providing a visual aid for discussion."
        }
    },
    {
        "utterance": "Kevin Cash: So yeah, here's here's what I've got now that from the scattered notes that I've been taking throughout the the session. So I listed some of the targets that we talked about that were good proxies, some general comments on tying it together. ",
        "annotations": {
            "summarize conversation": "Kevin Cash is summarizing the discussion by listing targets that were considered good proxies and making general comments on tying the information together."
        }
    },
    {
        "utterance": "Matt Bogyo: But I think some of the ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Kevin Cash: The things that are worth bringing up like I don't know if it's worth bringing up the challenges of individual modalities to the the whole group when we come back, but some of the discussions about like, okay, amplifying the signal, that seems like a higher value addition to to bring up for discussion with the other groups of because that seems at least to me like a big challenge moving forward is how do we get these low concentration signals that might be more beneficial than just, okay, things like blood flow or things like oxygen. How can we get low concentration things that might be valuable to have a signal big enough to measure. ",
        "annotations": {
            "develop idea": "Kevin is building upon previous discussions about challenges in measuring metabolites.",
            "ask question": "Kevin asks, 'How can we get low concentration things that might be valuable to have a signal big enough to measure.'",
            "identify gap": "Kevin points out the challenge of getting low concentration signals, implying a gap in current methods.",
            "offer feedback": "Kevin provides his perspective on what to discuss further.",
            "process management": "Kevin suggests a direction for future discussion."
        }
    },
    {
        "utterance": "Matt Bogyo: Yeah, I like it. I mean, I think I think having one of our main bullet points or discussion points for the for the for the for the end would be, yeah, these challenges and limitations associated with imaging metabolites in particular. Um, I guess the question is to what I think it's good to break it down to like two or three or maybe four at most kind of main points and then um, pick from the sort of notes you have which look quite quite good. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by suggesting how to organize discussion points."
        }
    },
    {
        "utterance": "Matt Bogyo: Um what are people's thoughts? ",
        "annotations": {
            "encourage participation": "The speaker invites others in the group to contribute their expertise, opinions, or ideas.",
            "ask question": "The speaker requests information, clarification, or opinions from other team members."
        }
    },
    {
        "utterance": "Katharine White: Yeah, I agree with that and I think this idea of amplification is important for for low abundant metabolites or oncometabolites or disease associated metabolites that might be important diagnostically. But I do think that Allison, I think made a good point about under certain conditions you may want the ability to to look at this dynamically and to look at metabolite production dynamically over a longer cellular process. ",
        "annotations": {
            "develop idea": "Katharine White is expanding on the idea of amplification for low abundant metabolites and discussing its implications.",
            "acknowledge contribution": "She acknowledges Allison's contribution about the need for dynamic observation of metabolite production.",
            "supportive response": "The utterance is supportive as it agrees with previous points and adds constructive comments to the discussion."
        }
    },
    {
        "utterance": "Katharine White: Which also has as we've discussed a lot of a lot of potential challenges in terms of being able to do that quantitatively. ",
        "annotations": {
            "develop idea": "The utterance builds upon previous discussions about challenges.",
            "identify gap": "The utterance mentions potential challenges in terms of being able to do something quantitatively."
        }
    },
    {
        "utterance": "Ping Wang: I I do like a context uh comment on the data like integration because the complexity of the metabolic metabolics uh so process. So um, I I think we should have a one um, one um point uh for the um integrated um data like for the all the uh information from imaging and also uh if you're talking about clinical application other uh features in clinic um for the diagnosis purpose um using um AI or deep learning. Probably we don't have many deep learning people here, nobody mentioned that. ",
        "annotations": {
            "develop idea": "The speaker expands on the discussion by suggesting the integration of data from imaging and clinical features for diagnosis.",
            "supportive response": "The speaker supports the idea of using integrated data and suggests using AI or deep learning for clinical applications.",
            "process management": "The speaker guides the discussion towards practical considerations for clinical applications and data integration."
        }
    },
    {
        "utterance": "Lingyan Shi: And uh um I think we perhaps can add a bio marker into this uh tool for diagnostic uh purpose because uh for example the amyloid beta protein it has a very specific peak in Raman region, Raman bands. It is separable from other protein. So as long as there is amyloid beta then we can detect it with the specific peak only belong to this molecule. ",
        "annotations": {
            "propose new idea": "Lingyan Shi suggests adding a biomarker for diagnostic purposes, introducing a new concept.",
            "develop idea": "Lingyan Shi elaborates on the idea by explaining how amyloid beta protein's specific peak in the Raman region can be used for detection."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): how we balance, you know, different things for different applications. Um, and then talked about complexity of data interpretation, that's one challenges, one of the challenges. Uh, any other um, challenges that people want to mention? Do we want to, I guess Kevin, one one of Kevin's questions is whether we go through the the challenges for individual modality or talk about a few shared or or or common, right? Um, critical challenges for imaging metabolites. ",
        "annotations": {
            "ask question": "The utterance explicitly asks questions about challenges and how to address them.",
            "process management": "The utterance manages the discussion flow by asking about challenges.",
            "clarify goal": "The utterance seeks to understand how to balance different aspects for imaging metabolites."
        }
    },
    {
        "utterance": "Allison Dennis, Boston U (she/her): think given the constraints of the the report out, keeping it to the general challenges, like there's always the challenge of signal to noise and the um, having enough signal for a small concentration analyte. Those things are endemic regardless of your modality. ",
        "annotations": {
            "process management": "Allison suggests managing the discussion by focusing on general challenges."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Looks like we got about five minutes here, so you may want to start to consolidate and get this onto the slide deck maybe. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by suggesting that the group consolidate their thoughts and prepare to present, given the limited time remaining."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: So what do you guys think is the most important other than the challenges? Like, do you think it's important to share with everyone some of the targets that we discussed? Do you think it's important to share some of these other questions we were talking about of heterogeneity or tying in genetics or focusing on talking about some other approaches? What do you guys think is most valuable for us to report back? ",
        "annotations": {
            "ask question": "The speaker is requesting thoughts and opinions from the group.",
            "process management": "The speaker is managing the discussion process by questioning what to focus on for reporting back.",
            "encourage participation": "The speaker is explicitly inviting others to contribute their thoughts."
        }
    },
    {
        "utterance": "Katharine White--Notre Dame: Um, I really liked, I think it was Candace's point about this um having a a genetic fingerprint or metabolomic fingerprint that that you could use diagnostically. Um, there's a lot of work that we need to do in order to, you know, identify the what what that fingerprint looks like um but I think that was a an interesting uh concept that from from our discussion that was exciting to me. ",
        "annotations": {
            "acknowledge contribution": "The speaker acknowledges Candace's previous point about genetic or metabolomic fingerprints.",
            "supportive response": "The speaker expresses agreement and interest in the concept of using genetic or metabolomic fingerprints diagnostically."
        }
    },
    {
        "utterance": "Lingyan Shi: ming establish a library for standard compounds that can be a target. ",
        "annotations": {
            "propose new idea": "The speaker introduces a new idea of establishing a library for standard compounds that can be a target."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: I think we're going to have to make some decisions here. We got two minutes or three minutes. We're going to be the first ones reporting out. So I I think uh, you know, I don't know, personally, I I can give you my opinion. I think I think that um this giving some overview of the kinds of metabolites that are being reported on, talking about the modalities that we discussed and and then going into the limitations would probably be the most useful information for people, I would say. ",
        "annotations": {
            "develop idea": "The speaker is developing the idea of how to approach their report-out by suggesting specific topics to cover.",
            "process management": "The speaker is guiding the process of their discussion and report-out.",
            "clarify goal": "The speaker is clarifying what they think should be the goals or content of their report-out."
        }
    },
    {
        "utterance": "Kevin Cash/CO Mines: What did you say for the first part? ",
        "annotations": {
            "ask question": "Kevin is requesting information or clarification about what was said earlier."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Like talking about the types of um metabolites that are imaged. So you have a nice kind of list there of things that are, you know, what is sort of the cutting edge and what are people looking at and then um I think mentioning the modalities that are used and then the limitations. I think that that was kind of the bulk of a lot of our discussion. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing what has been previously discussed by the group, highlighting key points such as the types of metabolites imaged, modalities used, and limitations."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah, that sounds great. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): So the the first uh bullet point. ",
        "annotations": {
            "process management": "Jin Zhang is referring to the first bullet point, indicating an effort to organize or structure the discussion."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Yeah, I know. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement or validation with a previous statement."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): and the limitations, right? And the modalities in the need. ",
        "annotations": {
            "summarize conversation": "The speaker is summarizing key points from the conversation, including limitations, modalities, and needs."
        }
    },
    {
        "utterance": "Lingyan Shi: I think I have a comments on the the and problem is a question driven or tech technical driven, maybe biological question driven will give us a very clear target molecule, so we can seek the tool easier. Find out which one is the best. ",
        "annotations": {
            "develop idea": "The speaker is expanding on the idea that research approaches should be guided by biological questions to identify clear target molecules.",
            "clarify goal": "The speaker is discussing the goal of having clear biological questions to guide research and tool development."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah, definitely uh we we kind of covered that sort of application based uh considerations, right? ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Great. Great discussions. Thanks everyone. ",
        "annotations": {
            "supportive response": "The speaker is expressing agreement and a positive evaluation of the discussions that took place, thanking everyone."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Thanks Matt. ",
        "annotations": {
            "acknowledge contribution": "The speaker is verbally recognizing another group member's input, in this case, thanking Matt for his role in leading the discussion."
        }
    },
    {
        "utterance": "Matt Bogyo - Stanford: Yep, thank you. Jen, we'll see you guys in the main room. ",
        "annotations": {
            "process management": "The speaker is managing the meeting flow by wrapping up the current discussion and instructing the group to move to the main room."
        }
    },
    {
        "utterance": "Jin Zhang (UCSD): Yeah. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lingyan Shi: Thank you. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lingyan Shi: Bye. ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Lingyan Shi: Thank you, Kevin. ",
        "annotations": {
            "acknowledge contribution": "The speaker verbally recognizes another group member's input, in this case, thanking Kevin for his contribution."
        }
    },
    {
        "utterance": "Silvia Ronco, RCSA:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    },
    {
        "utterance": "Aniruddha Ray:  ",
        "annotations": {
            "None": "No relevant code applies to this utterance"
        }
    }
]